Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−8.19 USD
−12.54 M USD
0.00 USD
1.40 M
About Salarius Pharmaceuticals, Inc.
Sector
Industry
CEO
David J. Arthur
Website
Headquarters
Houston
Founded
2014
FIGI
BBG00740LLD5
Salarius Pharmaceuticals, Inc. is a clinical-stage oncology company, which engages in the development of treatments for cancers with high, unmet medical need. Its pipeline includes SP-3164, a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. The company was founded in February 2014 and is headquartered in Houston, TX.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of SLRX is 1.33 USD — it has decreased by −5.69% in the past 24 hours. Watch Salarius Pharmaceuticals, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Salarius Pharmaceuticals, Inc. stocks are traded under the ticker SLRX.
SLRX stock has fallen by −9.39% compared to the previous week, the month change is a 0.46% rise, over the last year Salarius Pharmaceuticals, Inc. has showed a −74.81% decrease.
SLRX reached its all-time high on Apr 22, 2015 with the price of 124,100.00 USD, and its all-time low was 1.26 USD and was reached on Oct 14, 2024. View more price dynamics on SLRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
SLRX stock is 8.46% volatile and has beta coefficient of 0.73. Track Salarius Pharmaceuticals, Inc. stock price on the chart and check out the list of the most volatile stocks — is Salarius Pharmaceuticals, Inc. there?
Today Salarius Pharmaceuticals, Inc. has the market capitalization of 2.00 M, it has increased by 9.72% over the last week.
Yes, you can track Salarius Pharmaceuticals, Inc. financials in yearly and quarterly reports right on TradingView.
Salarius Pharmaceuticals, Inc. is going to release the next earnings report on Mar 31, 2025. Keep track of upcoming events with our Earnings Calendar.
SLRX net income for the last quarter is −972.12 K USD, while the quarter before that showed −1.42 M USD of net income which accounts for 31.75% change. Track more Salarius Pharmaceuticals, Inc. financial stats to get the full picture.
No, SLRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 18, 2024, the company has 2.00 employees. See our rating of the largest employees — is Salarius Pharmaceuticals, Inc. on this list?
Like other stocks, SLRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Salarius Pharmaceuticals, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Salarius Pharmaceuticals, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Salarius Pharmaceuticals, Inc. stock shows the sell signal. See more of Salarius Pharmaceuticals, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.